OncoMatch/Clinical Trials/NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Is NCT06787612 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for ovarian cancer.
Treatment: Ubamatamab · Bevacizumab · Cemiplimab · Fianlimab · PLD · Sarilumab — This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Platinum-Resistant Ovarian Cancer, as described in the protocol
Lab requirements
Blood counts
Adequate organ and bone marrow function, as described in the protocol
Kidney function
Adequate organ and bone marrow function, as described in the protocol
Liver function
Adequate organ and bone marrow function, as described in the protocol
Adequate organ and bone marrow function, as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Alabama at Birmingham · Birmingham, Alabama
- UC San Diego Health · La Jolla, California
- Cedars Sinai Medical Center · Los Angeles, California
- Mayo Clinic Jacksonville · Jacksonville, Florida
- University of Miami Sylvester Comprehensive Cancer Center · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify